SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid TumorsGlobeNewsWire • 12/27/22
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx ConferenceGlobeNewsWire • 11/22/22
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/03/22
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple MyelomaPRNewsWire • 11/01/22
Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a BetZacks Investment Research • 10/19/22
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell TumorsGlobeNewsWire • 09/29/22
SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple MyelomaGlobeNewsWire • 09/07/22
SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/04/22
SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/02/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the FirmNewsfile Corp • 06/24/22
SpringWorks Therapeutics to Present Progress Across the Company's Targeted Oncology Portfolio at Virtual R&D DayGlobeNewsWire • 06/10/22
SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare ConferenceGlobeNewsWire • 06/09/22
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meetingMarket Watch • 05/27/22
SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual MeetingGlobeNewsWire • 05/26/22
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting GoalZacks Investment Research • 05/25/22
SpringWorks shares jump 14%; company plans to seek FDA approval for desmoid tumor therapy this yearMarket Watch • 05/24/22
SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/05/22